Solid Tumors Clinical Trial
Official title:
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
Verified date | April 2020 |
Source | Incyte Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This was a study of INCB052793 given to patients with advanced malignancies that was to be conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and Phase 2 (Combination therapy of INCB052793 with azacitidine and itacitinib with azacitidine). Phase 1 had two parts; a dose escalation (Part 1) and an expansion (Part 2).
Status | Terminated |
Enrollment | 83 |
Est. completion date | February 27, 2019 |
Est. primary completion date | February 27, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Phase 1a - Aged 18 years or older - Histologically or cytologically confirmed solid tumor or hematologic malignancy - Life expectancy of 12 weeks or longer - Must have received = 1 prior treatment regimen - Must not be a candidate for potentially curative or standard of care approved therapy Phase 1b - Aged 18 years or older - Cohort A: Histologically or cytologically confirmed pancreatic adenocarcinoma, triple-negative breast cancer, urothelial cancer with at least 1 measurable or evaluable target lesion - Cohorts B, C, D, E and G: Histologically confirmed multiple myeloma and measureable/evaluable disease - Cohort F: Confirmed acute myeloid leukemia or myelodysplastic syndrome - Cohort H: Individuals diagnosed with lymphoma - Prior therapy: - Cohort A: No more than 1 prior chemotherapy regimen for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy) - Cohorts B, C, D, E and G: Must have relapsed from or have been refractory to = 2 prior treatment regimens - Cohort F: May have received any number of prior treatment regimens or be treatment-naïve - Cohort H: Must have relapsed from or have been refractory to available treatments Phase 2 - Aged 18 years or older - Cohorts I and J: Confirmed acute myeloid leukemia or high risk myelodysplastic syndrome - Prior therapy: - Cohorts I and J: Must have failed prior therapy with a hypomethylating agent (HMA) Exclusion Criteria: - Prior receipt of a JAK1 inhibitor (Phase 1a only) - Known active central nervous system metastases and/or carcinomatous meningitis - Eastern Cooperative Oncology Group (ECOG) performance status > 2 - Any known contraindications to the use of gemcitabine, nab-paclitaxel, dexamethasone, carfilzomib, bortezomib, lenalidomide, azacitidine, pomalidomide or PI3Kd inhibitor (Phase 1b and Phase 2 only, as appropriate to treatment cohort) - Known human immunodeficiency virus infection, or evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or risk of reactivation |
Country | Name | City | State |
---|---|---|---|
United States | Site 2 | Nashville | Tennessee |
Lead Sponsor | Collaborator |
---|---|
Incyte Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase 1a and 1b: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE) | An AE is any untoward medical occurrence in a subject administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization. A TEAE was defined as any AE either reported for the first time or worsening of a pre-existing event after first dose of study drug and within 30 days of the last dose of study drug. | From first dose of study drug up to 30 days after last dose of study drug (Up to approximately 3.4 years) | |
Primary | Phase 2: Objective Response Rate (ORR) in Hematological Malignancies | ORR is defined as the proportion of participants who achieved complete response (CR), CR with incomplete hematologic recovery (CRi), partial response (PR), or hematologic improvement (HI), using the IWG response criteria. | Baseline through end of study (Up to approximately 4.5 years) | |
Secondary | Phase 1A and 1B: Percentage of Participants With Response as Determined by Investigator's Assessment | Response rate is defined as the percentage of participants who achieved best overall response (BOR) as determined by IWG response criteria of investigator's assessment. A participant was considered an objective responder based on the following- Solid tumors: participant had a best overall response (BOR) of CR or PR, Lymphoma: participant had a BOR of complete radiologic response/complete metabolic response or partial remission/partial metabolic response, AML: participant had a BOR of CR, CRi, morphological leukemia-free state (MLFS), or PR, MDS: participant had a BOR of CR, PR, or marrow CR, MDS/myeloproliferative neoplasm (MPN): participant had a BOR of CR, PR, or marrow response, MM: participant had a BOR of stringent CR, CR, very good PR, PR, or MR. Subjects are combined by tumor type for this analysis. | Baseline through end of study (Up to approximately 4.5 years) | |
Secondary | Phase 2: Number of Participants With at Least One TEAE and SAE | An AE is any untoward medical occurrence in a subject administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization. A TEAE was defined as any AE either reported for the first time or worsening of a pre-existing event after first dose of study drug and within 30 days of the last dose of study drug. | From first dose of study drug up to 30 days after last dose of study drug (Up to approximately 1.3 years) | |
Secondary | Phase 1a, 1b, and Phase 2: Cmax: Maximum Observed Plasma Concentration for INCB052793 | Cmax is defined as the maximum observed plasma concentration measured at steady state (Day 15). For PK analyses subjects in TGA and TGB are combined by dosage group because only 3 subjects were enrolled in each dose group in TGB and 4 subject for first dose in TGB 50 mg. | Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2 | |
Secondary | Phase 1a, 1b, and Phase 2: Tmax: Time to Maximum Plasma Concentration for INCB052793 | Tmax is the time to maximum (peak) observed plasma drug concentration. Summary of Steady-State, Day 15, was evaluated by dosing regimen. For PK analyses subjects in TGA and TGB are combined by dosage group because only 3 subjects were enrolled in each dose group in TGB and 4 subject for first dose in TGB 50 mg. | Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2 | |
Secondary | Phase 1a, 1b, and Phase 2: AUC0-t: Area Under the Plasma Concentration-time Curve Over Dosing Interval for INCB052793 | AUC0-t is the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t measured at steady state (Day 15). For PK analyses subjects in TGA and TGB are combined by dosage group because only 3 subjects were enrolled in each dose group in TGB and 4 subject for first dose in TGB 50 mg. | Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2 | |
Secondary | Phase 1a, 1b, and Phase 2: Cmax: Maximum Observed Plasma Concentration of Itacitinib | Cmax is defined as the maximum observed plasma concentration measured at steady state (Day 15). | Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2 | |
Secondary | Phase 1a, 1b, and Phase 2: Tmax: Time to Maximum Plasma Concentration for Itacitinib | Tmax is the time to maximum (peak) observed plasma drug concentration. | Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2 | |
Secondary | Phase 1a, 1b, and Phase 2: AUC0-t: Area Under the Plasma Concentration-time Curve Over Dosing Interval for Itacitinib | AUC0-t is the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t measured at steady state (Day 15). | Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2 | |
Secondary | Phase 1a, Part 2: Cmax: Maximum Observed Plasma Concentration for INCB052793 | Cmax is defined as the maximum observed plasma concentration measured at Day 1. | Cycle 1, Day 1 | |
Secondary | Phase 1a, Part 2: Tmax: Time to Maximum Plasma Concentration for INCB052793 | Tmax is the time to maximum (peak) observed plasma drug concentration. | Cycle 1, Day 1 | |
Secondary | Phase 1a, Part 2: AUC[0-t]: Area Under the Plasma Concentration-Time Curve From Time 0 To the Last Measurable Concentration at Time t | AUC0-t is the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t. | Cycle 1, Day 1 | |
Secondary | Phase 1a, Part 2: Cmax: Maximum Observed Plasma Concentration for INCB052793 | Cmax is defined as the maximum observed plasma concentration measured at steady state (Day 15). | Cycle 1, Day 15 | |
Secondary | Phase 1a, Part 2: Cmin: Minimum Observed Plasma Concentration Over the Dose Interval | Minimum observed plasma concentration measured at steady state (Day 15). | Cycle 1, Day 15 | |
Secondary | Phase 1a, Part 2: Tmax: Time to Maximum Plasma Concentration for INCB052793 | Tmax is the time to maximum (peak) observed plasma drug concentration. | Cycle 1, Day 15 | |
Secondary | Phase 1a, Part 2: AUC[0-t]: Area Under the Plasma Concentration-Time Curve From Time 0 To the Last Measurable Concentration at Time | AUC0-t is the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t measured at steady state (Day 15). | Cycle 1, Day 15 | |
Secondary | Phase 1a, Part 2: AUC0-t: Area Under the Plasma Concentration-time Curve Over Dosing Interval for INCB052793 | AUC0-t is the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t. | Cycle 1, Day 15 | |
Secondary | Phase 1a, Part 2: Cmax: Maximum Observed Plasma Concentration for INCB052793 | Cmax is defined as the maximum observed plasma concentration measured at cycle 2 Day 1. | Cycle 2, Day 1 | |
Secondary | Phase 1a, Part 2: Cmin: Minimum Observed Plasma Concentration Over the Dose Interval | Cmin is defined as the minimal observed plasma concentration measured at cycle 2 Day 1 | Cycle 2, Day 1 | |
Secondary | Phase 1a, Part 2: Tmax: Time to Maximum Plasma Concentration for INCB052793 | Tmax is the time to maximum (peak) observed plasma drug concentration. | Cycle 2, Day 1 | |
Secondary | Phase 1a, Part 2: AUC[0-t]: Area Under the Plasma Concentration-Time Curve From Time 0 To the Last Measurable Concentration at Time | AUC0-t is the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t. | Cycle 2, Day 1 | |
Secondary | Phase 1a, Part 2: AUC0-t: Area Under the Plasma Concentration-time Curve Over Dosing Interval for INCB052793 | AUC0-t is the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t. | Cycle 2, Day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT01940601 -
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
|
Phase 2 |